Loading company…
Precigen develops gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen develops biopharmaceutical treatments, including PAPZIMEOS (zopapogene imadenovec-drba), and uses gene and cell therapy technologies. The company serves healthcare providers, hospitals, and specialty clinics, primarily in North America. Founded in 1998 in Germantown, US, it raised USD 75.00 mn in a Private Placement/Follow on round.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in